Omnicell Achieves Record Revenue in the Third Quarter 2015

Go back to Omnicell Achieves Record Revenue in the Third Quarter 2015

Lower Revenues and Guidance on Omnicell (OMCL) Raises Concerns; Cowen Cuts Price Target to $29

October 30, 2015 8:24 AM EDT

Cowen maintained a Market Perform rating on Omnicell (NASDAQ: OMCL), and cut the price target to $29.00 (from $37.00), following the company's 3Q earnings results. OMCL reported 3Q adjusted EPS of $0.36, in-line with consensus expectations. Revenues slightly missed this quarter coming in at $125.2M, up 11.3%... More

Omnicell (OMCL) Reports In-Line Q3 EPS; Announces $275M Acquisition of Aesynt

October 29, 2015 4:38 PM EDT

Omnicell (NASDAQ: OMCL) reported Q3 EPS of $0.36, in-line with the analyst estimate of $0.36. Revenue for the quarter came in at $125.2 million versus the consensus estimate of $128.54 million.

OMCL also announced it has entered into a definitive agreement to acquire Aesynt Incorporated. The acquisition would create the broadest product portfolio in the industry with significant offerings in automated dispensing systems, central pharmacy robotics, IV robotics and enterprise analytics. The combined company would support approximately 4,000 acute care facilities worldwide, have annual revenues of over $650 million and have approximately 2,200 employees.

"As hospitals... More